<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245556</url>
  </required_header>
  <id_info>
    <org_study_id>CA206-005</org_study_id>
    <nct_id>NCT01245556</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma</brief_title>
  <official_title>A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in
      combination with ipilimumab; and then to evaluate the anti-tumor response to BMS-908662 when
      administered in combination with ipilimumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3</measure>
    <time_frame>Assessments approximately every 3 weeks throughout the duration of the trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as determined by estimates of objective response rates and response duration</measure>
    <time_frame>Efficacy measured every 6 weeks until week 48, then every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for BMS-908662 as determined by minimum and maximum observed concentrations, time of maximum observed concentration, area under the concentration curve for one dosing interval and the accumulation index</measure>
    <time_frame>PK measured during first 4 weeks on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD will be assessed by evaluating markers of RAS/RAF pathway activity</measure>
    <time_frame>PD assessed during the first 4 weeks on study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>BMS-908662 or Ipilimumab (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-908662 or Ipilimumab (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-908662</intervention_name>
    <description>Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously</description>
    <arm_group_label>BMS-908662 or Ipilimumab (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-908662</intervention_name>
    <description>Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously</description>
    <arm_group_label>BMS-908662 or Ipilimumab (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously</description>
    <arm_group_label>BMS-908662 or Ipilimumab (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously</description>
    <arm_group_label>BMS-908662 or Ipilimumab (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Male and female subjects ≥ 18 years of age with a histologic or cytologic diagnosis of
             Stage III or Stage IV (unresectable) melanoma

          -  Enrollment to cohort expansion will be limited to only those subjects whose tumors
             demonstrate the B-Raf V600E mutation

          -  ECOG ≤ 1

          -  Adequate organ &amp; marrow function

        Exclusion:

          -  Uncontrolled or significant cardiovascular disease

          -  Cohort expansion: Prior therapy with a RAF inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jedd D. Wolchok, Md,Phd</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2010</study_first_submitted>
  <study_first_submitted_qc>November 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2010</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

